Impact of small residual setup errors after image guidance on heart dose and survival in non-small cell lung cancer treated with curative-intent radiotherapy.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
11 2020
Historique:
received: 01 10 2019
revised: 07 04 2020
accepted: 08 04 2020
pubmed: 4 5 2020
medline: 15 4 2021
entrez: 4 5 2020
Statut: ppublish

Résumé

A recent study of NSCLC patients showed small residual setup errors (shifts) in the direction of the heart following image-guidance were significantly related to overall survival. This study of the dosimetric effects of these residual shifts investigates the hypothesis that observed survival differences were related to a change in heart dose. Accumulated doses including shifts for each fraction were determined for 475 NSCLC patients. Planning CTs and corresponding dose distributions were deformed to a reference. Image-based data-mining techniques were then applied to the difference between the planned and accumulated dose (Δdose) to determine where Δdose relates to 1-year survival. The significance of Δdose in the identified region was assessed using multivariable Cox analysis. The cohort was then split into octiles, based upon planned dose to the region, and multivariable Cox analysis performed for each sub-cohort to explore the dose response relationship. The identified dose threshold for damage was then tested in an independent validation cohort of 1482 NSCLC patients from the same institution. Permutation testing identified a small region in the heart base where Δdose significantly correlated with 1-year survival. Δdose in this region showed no correlation with common clinical variables, and was significant in multivariable Cox regression (p < 0.001, hazard ratio 1.221/Gy), with increasing change in dose from plan resulting in greater risk of death. Octile analysis revealed Δdose to be significant only in the 7th octile, planning dose 16.2-23.4 Gy, suggesting a steep dose-effect relation for heart damage in this range. Taking 16.2 Gy as a conservative threshold dose, this result was successfully validated, with a significant difference being seen between patients with a region dose above or below 16.2 Gy. This study suggests the relation between residual set-up errors and survival is explained by changes in cardiac dose, and identifies an area at the heart base where dose is correlated with survival. Our results suggest the dose threshold for cardiac damage is between 16.2 and 23.4 Gy in the base of the heart, which was validated in an independent cohort. However, the dose effect in other regions of the heart should also be investigated.

Sections du résumé

BACKGROUND AND PURPOSE
A recent study of NSCLC patients showed small residual setup errors (shifts) in the direction of the heart following image-guidance were significantly related to overall survival. This study of the dosimetric effects of these residual shifts investigates the hypothesis that observed survival differences were related to a change in heart dose.
MATERIALS AND METHODS
Accumulated doses including shifts for each fraction were determined for 475 NSCLC patients. Planning CTs and corresponding dose distributions were deformed to a reference. Image-based data-mining techniques were then applied to the difference between the planned and accumulated dose (Δdose) to determine where Δdose relates to 1-year survival. The significance of Δdose in the identified region was assessed using multivariable Cox analysis. The cohort was then split into octiles, based upon planned dose to the region, and multivariable Cox analysis performed for each sub-cohort to explore the dose response relationship. The identified dose threshold for damage was then tested in an independent validation cohort of 1482 NSCLC patients from the same institution.
RESULTS
Permutation testing identified a small region in the heart base where Δdose significantly correlated with 1-year survival. Δdose in this region showed no correlation with common clinical variables, and was significant in multivariable Cox regression (p < 0.001, hazard ratio 1.221/Gy), with increasing change in dose from plan resulting in greater risk of death. Octile analysis revealed Δdose to be significant only in the 7th octile, planning dose 16.2-23.4 Gy, suggesting a steep dose-effect relation for heart damage in this range. Taking 16.2 Gy as a conservative threshold dose, this result was successfully validated, with a significant difference being seen between patients with a region dose above or below 16.2 Gy.
CONCLUSIONS
This study suggests the relation between residual set-up errors and survival is explained by changes in cardiac dose, and identifies an area at the heart base where dose is correlated with survival. Our results suggest the dose threshold for cardiac damage is between 16.2 and 23.4 Gy in the base of the heart, which was validated in an independent cohort. However, the dose effect in other regions of the heart should also be investigated.

Identifiants

pubmed: 32360033
pii: S0167-8140(20)30189-4
doi: 10.1016/j.radonc.2020.04.008
pmc: PMC7707351
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

177-182

Subventions

Organisme : Cancer Research UK
ID : C147/A18083
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C147/A25254
Pays : United Kingdom

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Références

Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1586-95
pubmed: 17394953
Med Dosim. 2010 Winter;35(4):287-96
pubmed: 19962877
Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):434-442
pubmed: 29908945
J Clin Oncol. 2017 May 1;35(13):1381-1383
pubmed: 28113024
IEEE Trans Med Imaging. 2002 Sep;21(9):1142-50
pubmed: 12564882
J Clin Oncol. 2017 May 1;35(13):1387-1394
pubmed: 28113017
J Clin Oncol. 2017 May 1;35(13):1395-1402
pubmed: 28301264
Semin Radiat Oncol. 2007 Oct;17(4):258-67
pubmed: 17903703
Lancet Oncol. 2015 Feb;16(2):187-99
pubmed: 25601342
Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):253-8
pubmed: 17448878
Radiother Oncol. 2012 Feb;102(2):309-14
pubmed: 21872956
Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):51-60
pubmed: 28816160
Radiat Oncol. 2013 Dec 23;8:293
pubmed: 24365155
Eur J Cancer. 2017 Nov;85:106-113
pubmed: 28898766
Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1350-65
pubmed: 11483348
Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):927-34
pubmed: 19095368

Auteurs

Corinne Johnson-Hart (C)

Manchester Cancer Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, UK; University of Manchester, Manchester Academic Health Science Centre, The Christie NHS Foundation Trust, UK. Electronic address: corinne.hart@christie.nhs.uk.

Gareth Price (G)

University of Manchester, Manchester Academic Health Science Centre, The Christie NHS Foundation Trust, UK.

Alan McWilliam (A)

Manchester Cancer Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, UK; University of Manchester, Manchester Academic Health Science Centre, The Christie NHS Foundation Trust, UK.

Andrew Green (A)

Manchester Cancer Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, UK.

Corinne Faivre-Finn (C)

Manchester Cancer Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, UK; University of Manchester, Manchester Academic Health Science Centre, The Christie NHS Foundation Trust, UK.

Marcel van Herk (M)

Manchester Cancer Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH